Bruce S. Johnson - Mar 23, 2023 Form 3 Insider Report for GLYCOMIMETICS INC (GLYC)

Role: SVP & Chief Commercial Officer
Signature: /s/ Brian F. Leaf, as attorney-in-fact
Stock symbol: GLYC
Transactions as of: Mar 23, 2023
Transactions value $: $0
Form type: 3
Date filed: 3/31/2023, 04:34 PM
Next filing: May 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GLYC	Common Stock						125K	Mar 23, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	GLYC	Employee Stock Option (right to buy)							Mar 23, 2023	Common Stock	235K	$1.07	Direct	F1
holding	GLYC	Employee Stock Option (right to buy)							Mar 23, 2023	Common Stock	200K	$2.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The award was comprised of (i) an option to purchase 200,000 shares of the Issuer's common stock, which vested as to 25% of the underlying shares on February 16, 2023 and which will vest as to the remaining shares in equal monthly installments over 36 months thereafter, and (ii) an option to purchase 35,000 shares of common stock, which will vest as to one-half of the underlying shares upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remaining one-half of the underlying shares upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.
F2	25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

Content

The award was comprised of (i) an option to purchase 200,000 shares of the Issuer's common stock, which vested as to 25% of the underlying shares on February 16, 2023 and which will vest as to the remaining shares in equal monthly installments over 36 months thereafter, and (ii) an option to purchase 35,000 shares of common stock, which will vest as to one-half of the underlying shares upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remaining one-half of the underlying shares upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.

25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.